| Literature DB >> 24993164 |
Maxim Ivanov1, Isabel Barragan1, Magnus Ingelman-Sundberg2.
Abstract
There are pronounced interindividual variations in drug metabolism, drug responses, and the incidence of adverse drug reactions. To a certain extent such variability can be explained by genetic factors, but epigenetic modifications, which are relatively scarcely described so far, also contribute. It is known that a novel class of drugs termed epidrugs intervene in the epigenetic control of gene expression, and many of these are now in clinical trials for disease treatment. In addition, disease prognosis and drug treatment success can be monitored using epigenetic biomarkers. Here we review these novel aspects in pharmacology and address intriguing future opportunities for gene-specific epigenetic editing.Keywords: 5-hydroxymethylcytosine; DNA methylation; epidrugs; epigenetic editing; histone modifications; pharmacoepigenetics
Mesh:
Year: 2014 PMID: 24993164 DOI: 10.1016/j.tips.2014.05.004
Source DB: PubMed Journal: Trends Pharmacol Sci ISSN: 0165-6147 Impact factor: 14.819